When a new class of weight-loss drugs began reaching US clinics, the promise was straightforward: help patients with obesity lose significant weight and keep it off. Clinical trials for GLP-1 agonists, including semaglutide and tirzepatide, showed average weight loss of 15 to 20 percent over two years, with meaningful improvements in blood sugar, blood pressure, and cholesterol. Yet as prescriptions surged, a quieter problem emerged. The starting dose a patient receives often has less to do with their physiology and more to do with the checkboxes on an insurance form.

A New Class of Drugs Meets an Old Bureaucracy

GLP-1 agonists are not new. They have been used for type-2 diabetes for over a decade. What changed is their repurposing for obesity. Semaglutide, sold under brand names like Ozempic and Wegovy, and tirzepatide, under Mounjaro and Zepbound, became household names after trial results showed double-digit weight loss. Demand exploded, and clinics across the US began prescribing them to patients with obesity, defined as a body mass index of 30 or higher, or 27 with at least one weight-related condition.

But the infrastructure to support this new demand was never built. Most weight-loss clinics operate within a fragmented insurance landscape. Each payer, whether a large employer plan, a state Medicaid program, or a private insurer, has its own formulary, its own prior-authorization requirements, and its own dose restrictions. What works for a patient in one plan may be entirely unavailable to another with the same clinical profile.

The result is a clinical practice gap. Evidence-based guidelines from professional societies recommend starting at a low dose and escalating gradually over weeks to minimize side effects. But many insurance forms list only a few fixed dose options, and some require prescribers to jump to a higher dose to reduce the number of refills they cover. Clinicians report filling out forms that force them to choose a dose that does not match the patient's needs, simply to get the medication approved.

This tension is not unique to GLP-1 drugs. Similar battles have played out with other specialty medications, such as certain cancer therapies and biologic agents for autoimmune conditions. But the sheer scale of GLP-1 prescribing, combined with their cost, which can exceed a thousand dollars a month without insurance, has made the problem more visible. A 2023 survey of endocrinologists found that roughly 28 percent cited prior authorization as the top barrier to prescribing these drugs, ahead of cost and patient concerns.

The Evidence Says Start Low, Go Slow—Unless the Form Says Otherwise

The clinical evidence for GLP-1 agonists is built on gradual dose escalation. The STEP trials, which tested semaglutide for weight loss, used a protocol that started patients at 0.25 mg once weekly and increased the dose every four weeks over 16 to 20 weeks to reach a maintenance dose of 2.4 mg. The SURMOUNT trials for tirzepatide followed a similar pattern, starting at 2.5 mg and doubling every four weeks to a maximum of 15 mg.

This gradual titration exists for a reason. GLP-1 agonists work by mimicking a hormone that slows gastric emptying and signals satiety. When the dose rises too quickly, patients often experience nausea, vomiting, and diarrhea. In trials, discontinuation due to side effects was higher in the rapid-escalation groups. A slower schedule helps patients adapt, both physically and psychologically.

Yet insurance forms rarely reflect this nuance. Many prior-authorization forms ask the prescriber to check a box for a specific starting dose, with no room for a taper schedule. Some plans mandate that patients begin at a higher dose, such as 1.0 mg for semaglutide, to reduce the number of boxes the insurer pays for. Others restrict the total duration of treatment to six months, ignoring the need for long-term maintenance.

Clinicians are caught in the middle. They know that starting at 1.0 mg increases the risk of side effects and dropout. But if they prescribe the lower dose, the form may be rejected, and the patient waits weeks for an appeal. In practice, many physicians choose the path of least resistance, prescribing the dose the form demands, even when they believe it is clinically suboptimal.

Prior Authorization: The Hidden Formulary Gatekeeper

Prior authorization, or PA, is a process insurers use to require approval before covering a medication. For GLP-1 agonists, PA is nearly universal. A clinician must submit a form documenting the patient's BMI, comorbidities, and previous weight-loss attempts. The form often includes a list of approved doses, and the prescriber must select one.

The problem is that PA forms are designed for administrative efficiency, not clinical flexibility. They treat all patients as if they have the same needs. A patient with type-2 diabetes who has been on metformin for years may tolerate a higher starting dose than a patient with obesity and no metabolic abnormalities. But the form does not ask for that distinction.

When a PA is denied, the burden shifts to the clinician. Appeals can take weeks, during which the patient remains untreated. Some clinicians report spending 13 minutes or more per prescription on PA paperwork, time that could be spent with patients. A 2023 survey by the American Medical Association found that nearly all physicians believe PA can lead to adverse health outcomes, and a majority report that PA delays necessary care.

The result is a system where the form becomes the de facto treatment protocol. A patient's starting dose is determined not by their kidney function, their tolerance for side effects, or their previous response to similar drugs, but by which box the insurer's software will accept. This is not evidence-based medicine; it is form-based medicine.

When the Formulary Overrides the Clinical Protocol

Consider a hypothetical but representative case. A 52-year-old woman with type-2 diabetes and a BMI of 35 is prescribed semaglutide. Her clinician, following guidelines, plans to start at 0.25 mg weekly and titrate up over several months. The insurance form, however, lists only two options: 0.5 mg and 1.0 mg. The clinician selects 1.0 mg to avoid a denial, knowing the patient is likely to experience nausea.

Within two weeks, the patient calls with severe vomiting and dehydration. She stops the medication and tells her clinician she will never try it again. The clinician wants to restart at a lower dose, but the insurer requires a new PA, and the form still does not include 0.25 mg. The patient is left without treatment, and her diabetes management suffers.

This scenario plays out in clinics across the country. A 2024 analysis of US insurance claims found that roughly 54 percent of patients who started a GLP-1 agonist discontinued within six months. While some of those discontinuations are due to cost or side effects, a significant portion can be traced to dose escalation that was too aggressive for the patient's tolerance.

The irony is that the insurer's goal, to reduce costs, is often undermined. A patient who stops treatment after a month has wasted the cost of the medication and may require more expensive interventions later, such as bariatric surgery or hospitalization for diabetes complications. The short-term savings from avoiding a lower dose are dwarfed by the long-term costs of untreated obesity.

The Dose–Response Mismatch in Real-World Clinics

Real-world data on GLP-1 agonists show a pattern that diverges sharply from clinical trials. In trials, patients are followed closely, with regular visits and dose adjustments. In practice, patients see their clinician every few months, and dose changes require a new prescription, often a new PA, and sometimes a new appeal.

Electronic health records (EHRs) do not typically include built-in support for GLP-1 titration. A clinician must manually calculate the next dose, write a new prescription, and hope the pharmacy and insurer process it without delay. This is a far cry from the controlled environment of a trial.

A 2024 analysis of US claims data found that the average patient who discontinued a GLP-1 agonist within six months had been on a dose that was, on average, lower than the maintenance dose used in trials. This suggests that many patients never reached an effective dose before stopping, either because they could not tolerate the rapid escalation or because the PA process stalled their progression.

The mismatch is not just about dosing; it is about expectations. Trials measure weight loss at 68 weeks, with strict adherence. In the real world, patients miss doses, experience side effects, and may not see immediate results. A patient who loses only 5 percent of their body weight in the first three months may feel discouraged, even though that is a clinically meaningful outcome.

The Hidden Costs of Administrative Waste

Beyond the direct impact on patients, the administrative burden of prior authorization carries significant economic and human costs. A 2023 study estimated that US physicians spend an average of 14 hours per week on PA-related activities, translating to billions of dollars in lost productivity annually. For a busy endocrinologist or obesity medicine specialist, this time is often taken from direct patient care, extending wait times for new consults and follow-ups.

In some practices, dedicated staff are hired solely to manage PA submissions and appeals. These staff members coordinate with insurance companies, fax documents, and track denials. The cost of this administrative overhead is rarely covered by reimbursement, and it contributes to the financial strain on primary care practices, which are already stretched thin.

Moreover, the delays caused by PA can have clinical consequences beyond obesity. For patients with type-2 diabetes, a prolonged wait for GLP-1 therapy may result in suboptimal glycemic control, increasing the risk of complications such as neuropathy, retinopathy, and cardiovascular events. A 2022 study in the journal Diabetes Care found that patients who experienced PA delays for GLP-1 drugs had higher HbA1c levels at six months compared to those who received timely approval.

The burden is not evenly distributed. Patients in rural areas or those with limited health literacy may be less able to navigate the appeal process. They may simply stop treatment when faced with a denial, without understanding that they have the right to a review. This exacerbates existing health disparities, making obesity care even more inequitable.

What a Smarter Prior-Authorization Design Could Look Like

Reforming prior authorization for GLP-1 agonists is possible, and some academic medical centers have piloted changes. One approach is to replace fixed dose lists with clinical criteria that allow for clinician judgment. For example, a form could ask for the patient's baseline BMI, renal function, and history of gastrointestinal disease, and then allow the prescriber to choose any starting dose within a range, rather than a single checkbox.

Another approach is to use step therapy, where the insurer requires a trial of a lower-cost alternative before approving a GLP-1. This can be reasonable, but it must be paired with clear, evidence-based criteria for when a GLP-1 is appropriate, and it must not force patients to fail on a drug that is unlikely to work.

Automatic approvals for patients who have already been on a stable dose for several months would reduce the burden of repeat PAs. Currently, many insurers require a new PA every six months, even for a patient who has responded well and has no side effects. This is pure bureaucracy.

Pilot programs at institutions like the University of Michigan and the Mayo Clinic have shown that reducing PA requirements for certain medications can improve adherence and reduce clinician burnout, without increasing overall costs. These programs are not perfect, but they demonstrate that the current system is not the only option.

For Clinicians: Navigating the Forms Without Compromising Care

Until systemic reform happens, clinicians must navigate the forms as they are. The first step is documentation. A PA form that clearly states the patient's BMI, comorbidities, and prior weight-loss attempts, along with a brief note on why a specific starting dose is chosen, is more likely to be approved. Including a peer-reviewed reference can also help.

When a PA is denied, clinicians should use the peer-to-peer review process. This allows a direct conversation with the insurer's medical director, who may be more flexible than a form. In many cases, a single phone call can resolve a denial that would otherwise take weeks to appeal.

For patients who are uninsured or underinsured, patient assistance programs offered by the drug manufacturers can provide the medication at reduced or no cost. These programs have income thresholds, but they are worth exploring for patients who would otherwise go without treatment.

Finally, tracking PA outcomes in your practice can reveal patterns. If a particular insurer consistently denies a certain dose, you can adjust your prescribing strategy or advocate for a formulary change. The goal is not to fight the system blindly, but to work within it while documenting the barriers for future reform.

This article is for informational purposes only and does not constitute personalized medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.